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Neutron Thei 
There have been six recent reports on the applica-
tion of neutrons to cancer therapy; they report on the 
biochemical and biophysical aspects of fast-neutron 
therapy, neutron-capture and neutron-conversion 
therapy with intermediate-range neutrons, the chem-
istry and physics of nuclides for neutron-capture ther-
apy, the localization of dyes and azoproteins in tumors, 
and a computer program for neutron-gamma radio-
biology. The series is highly comprehensive and 
reflects a significant advance in this area of research. 
Three applications of neutrons to the problem of 
• cancer therapy have been proposed: fast-neutron, 
neutron-capture, and neutron-conversion therapy. 
The latter two involve biochemical as well as bio-
physical problems. Workers on the biochemical and 
biophysical aspects have attempted to provide effec-
tive chemical agents by localization and distribution 
studies of various compounds in normal and tumor-
bearing animals. Studies have been implemented by 
synthesis of unavailable compounds, and by develop-
ment of analytical techniques applicable to determi-
nation of the nuclides of interest: 6'Li, 10 B, and 23°U. 
Attempts have been made also to ascertain the bio-
logical effectiveness of the intermediate-energy 
neutrons, proposed for therapeutic use, by straight-
forward studies of lethality in mice induced by mono-
energetic neutrons in the range between 0.01 and 1.0 
M ev. 
The article on neutron-capture and neutron-conver-
sion therapy with intermediate-range neutrons reports 
an examination of the parameters of systems involving 
intermediate-range neutrons. From theoretic studies 
it had been determined that beams of neutrons of 
intermediate energy (0.3-300 ke y) would be more 
effective than thermal or epithermal neutrons in
apy of Cancer 
destroying the neoplasm and leaving the normal 
tissue unharmed. - 
Boron-10 and 23 °U are determined to be the most 
promising nuclides for capture therapy. The chemical 
and physical characteristics of nuclides most pertinent 
to neutron-capture therapy have been studied and 
reported. The problem of poor neutron penetration.of 
the tumor tissue had been solved by application of 
narrow beams of intermediate-energy neutrons, but 
problems of adequate localization and dose distribu-
tion required further study. 
For effective neutron-capture therapy, it was nec-
essary to know whether a massive dose of labeled 
protein would localize in a tumor; that is, a dose large 
enough to yield concentrations (in a tumor) of at 
least 3.5 x 10 3 M of the nuclide undergoing neutron 
capture. Thus the localization of dyes and azoproteins 
in spontaneous or induced (but not implanted) tumors 
was studied. p-Aminophenyl arsonic acid was used as 
the protein carrier in the localization studies. 
Many problems arise in theoretical and experimen-
tal neutron-gamma radiobiology that are difficult to 
handle by simple approximations, by transport theory, 
or even by experimental methods. Good computational 
methods were needed as adjuncts to experiment, not 
only to provide guides for good experimental design, 
but also to permit extrapolation from experimental 
results into regions difficult to examine experimentally. 
A newly devised computer program, based on the 
Monte Carlo method, permits great flexibility in 
problem and yields highly detailed information even 
at the microscopic level. 
Also reported is investigatory development of a 
radiobiologically useful source of monoenergetic neu-
trons free of contaminating radiations and sufficiently 
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flexible to afford rapid irradiation of typical biological 
objects at neutron energies from epithermal to 2 Mev. 
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Notes: 
I. This information may interest all concerned with 
cancer or heart afflictions. 
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